Dynatronics (NASDAQ: DYNT) and Rockwell Medical (NASDAQ:RMTI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.
Get Dynatronics alerts:
This table compares Dynatronics and Rockwell Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Dynatronics has a beta of -0.6, suggesting that its stock price is 160% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.
Institutional & Insider Ownership
27.1% of Dynatronics shares are owned by institutional investors. Comparatively, 21.5% of Rockwell Medical shares are owned by institutional investors. 51.8% of Dynatronics shares are owned by company insiders. Comparatively, 15.9% of Rockwell Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Dynatronics and Rockwell Medical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Dynatronics||$35.76 million||0.67||-$1.86 million||($1.15)||-2.57|
|Rockwell Medical||$57.30 million||5.39||-$25.92 million||($0.51)||-11.71|
Dynatronics has higher earnings, but lower revenue than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations and price targets for Dynatronics and Rockwell Medical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Rockwell Medical has a consensus price target of $11.00, indicating a potential upside of 84.25%. Given Rockwell Medical’s higher possible upside, analysts clearly believe Rockwell Medical is more favorable than Dynatronics.
Dynatronics beats Rockwell Medical on 7 of the 13 factors compared between the two stocks.
Dynatronics Corporation designs, manufactures, distributes, and markets physical medicine products in the United States and internationally. It manufactures and sells electrotherapy, therapeutic ultrasound, phototherapy, thermal therapy, iontophoresis devices, and other modalities; traction therapy equipment; and medical supplies and soft goods, including hot and cold packs, lumbar rolls, exercise balls, wrist splints, ankle weights, cervical collars and pillows, slings, bolsters, positioning wedges, back cushions, weight racks, rehabilitation products, back and wrist braces. The company also sells mat platforms, and other rehabilitation and athletic training room products. In addition, it distributes additional exercise equipment, treatment tables, parallel bars, hand therapy products, hot and cold therapy products, lotions and gels, paper products, athletic tape, splints, elastic wraps, exercise weights, exercise bands and tubing, walkers, treadmills, stair climbers, heating units for hot packs, whirlpools, electrodes, hydrotherapy and aquatic exercise products, clinical supplies, diagnostic and evaluation products, orthopedic supports, patient positioners, rehabilitation equipment, traction equipment, wound and edema care products, nutritional supplements, and portable electrotherapy products. The company sells its products to licensed practitioners, such as physical therapists, chiropractors, athletic trainers, professional sports teams and universities, sports medicine specialists, post-acute care facilities, hospitals and clinics through direct sales representatives and independent dealers, as well as through its e-commerce Websites and product catalogs. It also exports its products to approximately 30 countries. The company was founded in 1979 and is headquartered in Cottonwood Heights, Utah.
About Rockwell Medical
Rockwell Medical, Inc. operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment. It also provides Calcitriol, a generic active vitamin D injection, which is indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its concentrated dialysate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. The company's target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.